Compare RHI & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | TVTX |
|---|---|---|
| Founded | 1948 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.3B |
| IPO Year | 1994 | 2013 |
| Metric | RHI | TVTX |
|---|---|---|
| Price | $42.49 | $65.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $30.33 | ★ $40.62 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 8.68% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $5,378,506,000.00 | N/A |
| Revenue This Year | $1.27 | $44.76 |
| Revenue Next Year | $5.95 | $35.51 |
| P/E Ratio | $107.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.83 | $22.06 |
| 52 Week High | $46.70 | $68.03 |
| Indicator | RHI | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 60.45 |
| Support Level | $26.19 | $53.76 |
| Resistance Level | $46.70 | $66.24 |
| Average True Range (ATR) | 1.44 | 1.98 |
| MACD | -0.44 | -0.14 |
| Stochastic Oscillator | 13.72 | 71.85 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.